{"title":"Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time?","authors":"Iole Cucinotto, Lucia Fiorillo, Simona Gualtieri, Mariamena Arbitrio, Domenico Ciliberto, Nicoletta Staropoli, Anna Grimaldi, Amalia Luce, Pierfrancesco Tassone, Michele Caraglia, Pierosandro Tagliaferri","doi":"10.1155/2013/905091","DOIUrl":null,"url":null,"abstract":"<p><p>Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer. A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment. This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms.</p>","PeriodicalId":15575,"journal":{"name":"Journal of drug delivery","volume":"2013 ","pages":"905091"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/905091","citationCount":"62","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of drug delivery","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2013/905091","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/5/2 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 62
Abstract
Nanoparticle albumin bound paclitaxel (nab-paclitaxel) represents the first nanotechnology-based drug in cancer treatment. We discuss the development of this innovative compound and report the recent changing-practice results in breast and pancreatic cancer. A ground-breaking finding is the demonstration that nab-paclitaxel can not only enhance the activity and reduce the toxicity of chromophore-diluted compound, but also exert activity in diseases considered refractory to taxane-based treatment. This is the first clinical demonstration of major activity of nanotechnologically modified drugs in the treatment of human neoplasms.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
